A Myriad Genetics-funded team found that an 86-SNV polygenic score could modify breast cancer risk in women with pathogenic mutations in cancer risk genes.
Comprehensive analysis by a team led by Elaine Mardis has given 93 percent of around 150 pediatric cancer patients at least one medically actionable finding.
Christiana Care researchers have identified a unique protospacer adjacent motif site that allows them to knock out the NRF2 gene in tumor cells while leaving normal cells alone.
